Malaysian Health Ministry Set to Propose Public Health Smoking Control Act 2023

Regulations by 2FIRSTS.ai
Nov.28.2023
Malaysian Health Ministry Set to Propose Public Health Smoking Control Act 2023
Malaysia's Health Ministry plans to introduce the Public Health Control of Smoking Products Act 2023 to regulate harmful tobacco products.

According to a report by TheEdgeMarkets on November 22nd, the Malaysian Ministry of Health is ensuring that the "2023 Public Health Control of Smoking Products Bill" will be presented before the end of the parliamentary session on November 30th. This move aims to address the legal loophole regarding the exclusion of nicotine gel in the 1952 Dangerous Drugs Act.

 

Minister of Health Zaliha Mustafa stated that this legislation aims to comprehensively regulate smoking products that have been scientifically proven to be harmful to one's health.

 

After considering the views of the Attorney General, the Ministry of Health will revise the bill for the proposal in the upcoming cabinet meeting this Friday.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
Morocco rolls out compulsory rules for e-cigarettes, muassel and nicotine pouches
Morocco rolls out compulsory rules for e-cigarettes, muassel and nicotine pouches
Starting February 2026, Morocco will apply its first mandatory standard governing “smoke-free” products—covering e-cigarettes, muassel and nicotine pouches. Drafted by IMANOR, the standard introduces detailed requirements on composition, labelling, traceability and safety, and will apply to imported products. Consumer advocates say clear labelling and traceability are essential, while urging stronger public-awareness efforts and resources.
Feb.03 by 2FIRSTS.ai
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
Texas college data show rapid shifts in top vaping brands, with Geek Bar/Vape surging by 2025
Texas college data show rapid shifts in top vaping brands, with Geek Bar/Vape surging by 2025
A short communication in Drug and Alcohol Dependence examined changes in the most commonly used nicotine vaping brands among Texas college students from 2023 to 2025. The study analyzed 6,049 students aged 18–25 who reported past-30-day nicotine vaping across three repeated cross-sectional spring surveys. The report found that use of Esco Bar, Elf Bar, JUUL, and Puff Bar declined from 2023 to 2025, while Geek Bar/Vape increased.
Feb.27 by 2FIRSTS.ai
BENDSTA Urges Prime Minister to Review Bangladesh’s 2025 Tobacco Control Ordinance
BENDSTA Urges Prime Minister to Review Bangladesh’s 2025 Tobacco Control Ordinance
The Bangladesh Electronic Nicotine Delivery System Traders Association (BENDSTA) has urged the prime minister to initiate a comprehensive parliamentary review of the Smoking and Tobacco Products Use (Control) Ordinance, 2025.
Mar.12 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24